- Jack, Clifford R;
- Barnes, Josephine;
- Bernstein, Matt A;
- Borowski, Bret J;
- Brewer, James;
- Clegg, Shona;
- Dale, Anders M;
- Carmichael, Owen;
- Ching, Christopher;
- DeCarli, Charles;
- Desikan, Rahul S;
- Fennema‐Notestine, Christine;
- Fjell, Anders M;
- Fletcher, Evan;
- Fox, Nick C;
- Gunter, Jeff;
- Gutman, Boris A;
- Holland, Dominic;
- Hua, Xue;
- Insel, Philip;
- Kantarci, Kejal;
- Killiany, Ron J;
- Krueger, Gunnar;
- Leung, Kelvin K;
- Mackin, Scott;
- Maillard, Pauline;
- Malone, Ian B;
- Mattsson, Niklas;
- McEvoy, Linda;
- Modat, Marc;
- Mueller, Susanne;
- Nosheny, Rachel;
- Ourselin, Sebastien;
- Schuff, Norbert;
- Senjem, Matthew L;
- Simonson, Alix;
- Thompson, Paul M;
- Rettmann, Dan;
- Vemuri, Prashanthi;
- Walhovd, Kristine;
- Zhao, Yansong;
- Zuk, Samantha;
- Weiner, Michael
Introduction
Alzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.Methods
We review the contributions of the MRI core from present and past cycles of ADNI (ADNI-1, -Grand Opportunity and -2). We also review plans for the future-ADNI-3.Results
Contributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials.Discussion
Over the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future.